First Time Loading...

ReproCell Inc
TSE:4978

Watchlist Manager
ReproCell Inc Logo
ReproCell Inc
TSE:4978
Watchlist
Price: 155 JPY -0.64% Market Closed
Updated: Mar 28, 2024

Intrinsic Value

ReproCELL Inc. engages in stem cell research. [ Read More ]

The intrinsic value of one ReproCell Inc stock under the Base Case scenario is 159.7 JPY. Compared to the current market price of 155 JPY, ReproCell Inc is Undervalued by 3%.

Key Points:
Intrinsic Value
Base Case
159.7 JPY
Undervaluation 3%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
ReproCell Inc

Backtest ReproCell Inc Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling ReproCell Inc stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Financials

Balance Sheet Decomposition
ReproCell Inc

Current Assets 7.2B
Cash & Short-Term Investments 6.4B
Receivables 391.9m
Other Current Assets 466.9m
Non-Current Assets 1.1B
Long-Term Investments 960.6m
PP&E 126.8m
Intangibles 25.3m
Other Non-Current Assets 33.9m
Current Liabilities 580.1m
Accounts Payable 119.1m
Accrued Liabilities 4.8m
Other Current Liabilities 456.3m
Non-Current Liabilities 47.3m
Other Non-Current Liabilities 47.3m
Efficiency

Earnings Waterfall
ReproCell Inc

Revenue
2.5B JPY
Cost of Revenue
-1.4B JPY
Gross Profit
1.1B JPY
Operating Expenses
-1.5B JPY
Operating Income
-438.3m JPY
Other Expenses
220.8m JPY
Net Income
-217.5m JPY

Free Cash Flow Analysis
ReproCell Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

Profitability Score
Profitability Due Diligence

ReproCell Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 3-Years Revenue Growth
ROIC is Increasing
ROE is Increasing
32/100
Profitability
Score

ReproCell Inc's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

ReproCell Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

ReproCell Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
ReproCell Inc

Wall Street analysts forecast ReproCell Inc stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ReproCell Inc is 270 JPY .

Lowest
Price Target
Not Available
Average
Price Target
270 JPY
74% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
ReproCell Inc

1M 1M
-9%
6M 6M
-36%
1Y 1Y
-35%
3Y 3Y
-62%
5Y 5Y
-36%
10Y 10Y
-84%
Annual Price Range
155
52w Low
155
52w High
324
Price Metrics
Average Annual Return 15.54%
Standard Deviation of Annual Returns 59.37%
Max Drawdown -69%
Shares Statistics
Market Capitalization 13.2B JPY
Shares Outstanding 87 662 444
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

ReproCell Inc Logo
ReproCell Inc

Country

Japan

Industry

Biotechnology

Market Cap

13.2B JPY

Dividend Yield

0%

Description

ReproCELL Inc. engages in stem cell research. The company is headquartered in Yokohama, Kanagawa-Ken and currently employs 106 full-time employees. The company went IPO on 2013-06-26. The firm operates its business in two segments. The IPS Cell segment deals with regenerative medicine focused on Human ES (embryonic stem) cells and human iPS (induced pluripotent stem) cells. This segment manufactures research reagents used in human ES / iPS cell research, such as culture fluid, peeling liquid, frozen preservation solution, coating agents and antibody. The Clinical Testing segment clinical testing services that is required by hematopoietic stem cell transplantation and organ transplantation.

Contact

KANAGAWA-KEN
Yokohama
9F, Metlife Shin-Yokohama Bldg., 3-8-11, Shin-Yokohama, Kohoku-ku
+81454753887.0
https://reprocell.co.jp/

IPO

2013-06-26

Employees

106

Officers

CEO, President & Representative Director
Dr. Shuji Yokoyama Ph.D.
COO & Director
Mr. Daisuke Usui
CEO of REPROCELL USA Ltd & CEO of Bioserve Biotechnologies India
Mr. Ramakrishna V. Modali
Chief Executive officer of REPROCELL Europe
Dr. David Bunton

See Also

Discover More
What is the Intrinsic Value of one ReproCell Inc stock?

The intrinsic value of one ReproCell Inc stock under the Base Case scenario is 159.7 JPY.

Is ReproCell Inc stock undervalued or overvalued?

Compared to the current market price of 155 JPY, ReproCell Inc is Undervalued by 3%.